Quality of life in men with Klinefelter syndrome: a multicentre study.
Klinefelter syndrome
disorders/differences of sex development
multicentre study
quality of life
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
26
05
2023
accepted:
14
08
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Klinefelter syndrome (KS) is associated with an increased risk of lower socioeconomic status and a higher risk for morbidity and mortality, which may have a significant impact on quality of life (QOL). The objective of this study is to investigate QOL in a large European cohort of men with KS. Cross-sectional multicentre study. Two-hundred-eighteen men with KS were recruited from 14 clinical study centres in 6 European countries which participated in the European dsd-LIFE study. Male normative data from a healthy and a psychiatric reference population were used for comparison. The validated World Health Organization (WHO) QOL (WHOQOL)-BREF questionnaire was used to investigate five main domains of quality of life (WHOQOL): global, physical, psychological, environment, and social. The QOL physical domain score was lower for men with KS compared to the healthy reference population (KS: 66.9; s.d. 19.4, n = 193; healthy reference population: 76.5; s.d. 16.2, n = 1324, P < 0.001) but higher compared to the psychiatric reference population (54.6; s.d. 20.6; n = 77, P < 0.001). The WHOQOL-psychological domain score was lower for men with KS compared to the healthy reference population (KS: 63.6; s.d. 17.8, n = 193; healthy reference population: 67.8; s.d. 15.6, n = 1324, P < 0.05) but higher compared to the psychiatric reference population (45.9; s.d. 26.0), n = 77, P < 0.001). The social domain score on the WHOQOL questionnaire was found to be lower in men with Klinefelter syndrome (KS) compared to the healthy reference population (KS: 60.0; s.d. 21.6, n = 193; healthy reference population: 68.2; s.d. 13.8, n = 1324, P < 0.001). However, this score was similar to that of the psychiatric reference population (61.0; s.d. 17.0, n = 77, P = 0.5). The WHO environment domain score of men with KS (70.0; s.d. 15.0, n = 193) was similar to the healthy reference population (70.5; s.d. 20.7, n = 1324) but higher compared to the psychiatric reference population (61.9; s.d. 20.8, n = 77, P = 0.002). Experienced discrimination, less social activities, and the presence of chronic health problems were associated with significantly decreased QOL in men with KS. Overall QOL in European men with KS is significantly worse compared to a healthy European reference population. Especially, the presence of discrimination, less social activities, and chronic health problems is associated with lower physical, psychological, and social QOL. Further studies are necessary to investigate if a multidisciplinary approach may help to provide adequate counselling and psychosocial support to improve QOL.
Sections du résumé
Background
UNASSIGNED
Klinefelter syndrome (KS) is associated with an increased risk of lower socioeconomic status and a higher risk for morbidity and mortality, which may have a significant impact on quality of life (QOL). The objective of this study is to investigate QOL in a large European cohort of men with KS.
Design
UNASSIGNED
Cross-sectional multicentre study.
Methods
UNASSIGNED
Two-hundred-eighteen men with KS were recruited from 14 clinical study centres in 6 European countries which participated in the European dsd-LIFE study. Male normative data from a healthy and a psychiatric reference population were used for comparison. The validated World Health Organization (WHO) QOL (WHOQOL)-BREF questionnaire was used to investigate five main domains of quality of life (WHOQOL): global, physical, psychological, environment, and social.
Results
UNASSIGNED
The QOL physical domain score was lower for men with KS compared to the healthy reference population (KS: 66.9; s.d. 19.4, n = 193; healthy reference population: 76.5; s.d. 16.2, n = 1324, P < 0.001) but higher compared to the psychiatric reference population (54.6; s.d. 20.6; n = 77, P < 0.001). The WHOQOL-psychological domain score was lower for men with KS compared to the healthy reference population (KS: 63.6; s.d. 17.8, n = 193; healthy reference population: 67.8; s.d. 15.6, n = 1324, P < 0.05) but higher compared to the psychiatric reference population (45.9; s.d. 26.0), n = 77, P < 0.001). The social domain score on the WHOQOL questionnaire was found to be lower in men with Klinefelter syndrome (KS) compared to the healthy reference population (KS: 60.0; s.d. 21.6, n = 193; healthy reference population: 68.2; s.d. 13.8, n = 1324, P < 0.001). However, this score was similar to that of the psychiatric reference population (61.0; s.d. 17.0, n = 77, P = 0.5). The WHO environment domain score of men with KS (70.0; s.d. 15.0, n = 193) was similar to the healthy reference population (70.5; s.d. 20.7, n = 1324) but higher compared to the psychiatric reference population (61.9; s.d. 20.8, n = 77, P = 0.002). Experienced discrimination, less social activities, and the presence of chronic health problems were associated with significantly decreased QOL in men with KS.
Conclusion
UNASSIGNED
Overall QOL in European men with KS is significantly worse compared to a healthy European reference population. Especially, the presence of discrimination, less social activities, and chronic health problems is associated with lower physical, psychological, and social QOL. Further studies are necessary to investigate if a multidisciplinary approach may help to provide adequate counselling and psychosocial support to improve QOL.
Identifiants
pubmed: 37578764
doi: 10.1530/EC-23-0111
pii: EC-23-0111
pmc: PMC10563591
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Am Heart J. 2017 Jan;183:54-61
pubmed: 27979042
Health Qual Life Outcomes. 2011 Dec 19;9:115
pubmed: 22182307
Genet Med. 2011 Jul;13(7):632-42
pubmed: 21546843
BMC Endocr Disord. 2017 Aug 18;17(1):52
pubmed: 28821302
Qual Life Res. 2004 Mar;13(2):299-310
pubmed: 15085902
Arch Dis Child. 1999 Feb;80(2):192-5
pubmed: 10325742
J Autism Dev Disord. 2008 Oct;38(9):1634-41
pubmed: 18324463
J Clin Endocrinol Metab. 2003 Feb;88(2):622-6
pubmed: 12574191
Genet Med. 2018 Feb;20(2):214-222
pubmed: 28726803
Endocr Connect. 2022 Jun 29;11(7):
pubmed: 35700267
J Genet Couns. 2017 Aug;26(4):728-737
pubmed: 27832510
J Pediatr. 2015 Sep;167(3):650-7
pubmed: 26205184
J Clin Endocrinol Metab. 2005 Dec;90(12):6516-22
pubmed: 16204366
Am J Med Genet. 1999 Apr 16;88(2):200-6
pubmed: 10206242
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
Qual Life Res. 2001;10(8):711-21
pubmed: 11871592
Health Expect. 2012 Mar;15(1):49-62
pubmed: 21281412
J Clin Endocrinol Metab. 2006 Apr;91(4):1254-60
pubmed: 16394093
Acta Paediatr. 2011 Jun;100(6):807-13
pubmed: 21414026
Curr Opin Pediatr. 2015 Dec;27(6):748-56
pubmed: 26474342
Adv Pediatr. 2016 Aug;63(1):15-46
pubmed: 27426894
Patient Educ Couns. 2015 Jan;98(1):90-5
pubmed: 25239793